Sumitomo Dainippon Pharma

CompanyJapan

Sumitomo Dainippon Pharma develops one asset, preclinical (imeglimin in diabetic neuropathy). Mostly small molecule acting on Oxidative stress and ROS signalling, Mitochondrial biogenesis (PGC-1α) and sirtuin signalling; based in Japan.

1
Asset
Furthest stage: Preclinical; 0
Trials: 1
Signal

Pipeline

1

imeglimin
Improves mitochondrial function, reduces oxidative stress, increases intracellular NAD+, and suppresses high glucose-induced cellular senescence.
Preclinical, Small molecule, Oxidative stress and ROS signalling, Mitochondrial biogenesis (PGC-1α), diabetic neuropathy

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms6
Signals3
Similar companies6

Papers

Effect of Luseogliflozin on Myocardial Flow Reserve in Patients with Type 2 Diabetes Mellitus (LUCENT-J Study)
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Imeglimin and Nicotinamide Mononucleotide Ameliorate High Glucose–Induced Mitochondrial Dysfunction and Senescence in Schwann Cells
ADA Scientific Sessions 2026 abstract, 5 Jun 2026
Development and Validation of a Risk Score for Predicting the Initiation of Dialysis in People with and without Diabetes Mellitus
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Enhanced Renal Protective Effects of Tirzepatide in T2D People
ADA Scientific Sessions 2025 abstract, 13 Jun 2025
Prediction of the Development of Diabetes and Comorbidities by Time Spent in a Unipodal Stance with Eyes Closed
ADA Scientific Sessions 2025 abstract, 13 Jun 2025